The 142 references in paper S. Avdeev N., С. Авдеев Н. (2016) “ПРОФИЛАКТИКА ОБОСТРЕНИЙ ХРОНИЧЕСКОЙ ОБСТРУКТИВНОЙ БОЛЕЗНИ ЛЕГКИХ // PREVENTION OF ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE” / spz:neicon:pulmonology:y:2016:i:5:p:591-603

1
Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of chronic obstructive pulmonary disease. Revised 2016. www.goldcopd.org
(check this in PDF content)
2
Lopez A.D., Shibuya K., Rao C. et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur. Respir. J. 2006; 27: 397–412.
(check this in PDF content)
3
Gershon A.S., Dolmage T.E., Stephenson A., Jackson B. Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD. 2012; 9: 216–226.
(check this in PDF content)
4
Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med.2010; 363: 1128–1138.
(check this in PDF content)
5
AgustíA., Calverley P.M., Decramer M. et al. Prevention of exacerbations in chronic obstructive pulmonary disease: knowns and unknowns. J. COPD F.2014; 1 (2): 166–184. DOI:http:// dx.doi.org/10.15326/jcopdf.1.2.2014.0134.
(check this in PDF content)
6
Bhowmik A., Seemungal T.A., Sapsford R.J. et al. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000; 55: 114–120.
(check this in PDF content)
7
Celli B., ZuWallack R., Wang S. et al. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest. 2003; 124: 1743–1748.
(check this in PDF content)
8
Qiu Y., Zhu J., Bandi V. et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe http://journal.pulmonology.ru exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 168: 968–975.
(check this in PDF content)
9
Wilkinson T.M., Hurst J.R., Perera W.R. et al. Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. Chest. 2006; 129: 317–324.
(check this in PDF content)
10
Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370: 786–796.
(check this in PDF content)
11
Celli B.R., Barnes P.J. Exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J.2007; 29: 1224–1238.
(check this in PDF content)
12
Seemungal T., Harper-Owen R., Bhowmik A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2001; 164: 1618–1623.
(check this in PDF content)
13
Sethi S., Evans N., Grant B.J. et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med.2002; 347: 465–471.
(check this in PDF content)
14
Papi A., Bellettato C.M., Braccioni F. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173: 1114–1121.
(check this in PDF content)
15
Quint J.K., Donaldson G.C., Hurst J.R. et al. Predictive accuracy of patient-reported exacerbation frequency in COPD. Eur. Respir. J. 2011; 37: 501–507.
(check this in PDF content)
16
Seemungal T.A., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.1998; 157: 1418–1422.
(check this in PDF content)
17
Hurst J.R., Donaldson G.C., Quint J.K. et al. Temporal clustering of exacerbations in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2009; 179: 369–374.
(check this in PDF content)
18
Perera W.R., Hurst J.R., Wilkinson T.M. et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur. Respir. J. 2007; 29: 527–534.
(check this in PDF content)
19
Wedzicha J., Decramer M., Seemungal T. The role of bronchodilator treatment in the prevention of exacerbations of COPD. Eur. Respir. J.2012; 40: 1545–1554.
(check this in PDF content)
20
Langsetmo L., Platt R.W., Ernst P. et al. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort.Am. J. Respir. Crit. Care Med.2008; 177: 396–401.
(check this in PDF content)
21
Wilkinson T.M., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2004; 169: 1298–1303.
(check this in PDF content)
22
Barbera J.A., Roca J., Ferrer A. et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 1997; 10: 1285–1291.
(check this in PDF content)
23
Casadevall C., Coronell C., Ramirez-Sarmiento A.L. et al. Upregulation of pro-inflammatory cytokines in the intercostal muscles of COPD patients.Eur. Respir. J. 2007; 30: 701–701.
(check this in PDF content)
24
Hogg J.C., Chu F., Utokaparch S. et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med.2004; 350: 2645–2653.
(check this in PDF content)
25
Wedzicha J.A., Hurst J.R. Structural and functional coconspirators in chronic obstructive pulmonary disease exacerbations.Proc. Am. Thorac. Soc. 2007; 4: 602–605.
(check this in PDF content)
26
Saha S., Brightling C.E. Eosinophilic airway inflammation in COPD.Int. J. Chron. Obstruct. Pulm. Dis. 2006; 1: 39–47.
(check this in PDF content)
27
Siva R., Green R.H., Brightling C.E. et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial.Eur. Respir. J.2007; 29: 906–913.
(check this in PDF content)
28
Bafadhel M., McKenna S., Terry S. et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med.2011; 184: 662–671.
(check this in PDF content)
29
Hoogendoorn M., Hoogenveen R.T., Rutten-van Molken M.P. et al. Case fatality of COPD exacerbations: a meta-analysis and statistical modelling approach. Eur. Respir. J. 2011; 37: 508–515.
(check this in PDF content)
30
Suissa S., Dell'aniello S., Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67: 957–963.
(check this in PDF content)
31
Donaldson G.C., Seemungal T.A., Bhowmik A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002; 57: 847–852.
(check this in PDF content)
32
Donaldson G.C., Seemungal T.A., Patel I.S. et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest. 2005; 128: 1995–2004.
(check this in PDF content)
33
Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P. et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005; 60: 925–931.
(check this in PDF content)
34
Miravitlles M., Ferrer M., Pont A. et al. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004; 59: 387–395.
(check this in PDF content)
35
Bernard S., LeBlanc P., Whittom F. et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med.1998; 158: 629–634.
(check this in PDF content)
36
Cazzola M., MacNee W., Martinez F.J. et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers.Eur. Respir. J.2008; 31: 416–469.
(check this in PDF content)
37
Mannino D.M., Watt G., Hole D. et al. The natural history of chronic obstructive pulmonary disease.Eur. Respir. J. 2006; 27: 627–643.
(check this in PDF content)
38
Niewoehner D.E., Rice K., Cote C. et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann. Intern. Med. 2005; 143: 317–326.
(check this in PDF content)
39
Spruit M.A., Gosselink R., Troosters T. et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax. 2003; 58: 752–756.
(check this in PDF content)
40
Wedzicha J.A., Donaldson G.C. Exacerbations of chronic obstructive pulmonary disease. Respir. Care. 2003; 48: 1204–1213.
(check this in PDF content)
41
Spencer S., Jones P.W. Time course of recovery of health status fol-lowing an infective exacerbation of chronic bronchitis. Thorax. 2003; 58: 589–593.
(check this in PDF content)
42
Cote C.G., Dordelly L.J., Celli B.R. Impact of COPD exacerbations on patient-centered outcomes. Chest. 2007; 131: 696–704.
(check this in PDF content)
43
Kanner R.E., Anthonisen N.R., Connett J.E. Lower respiratory illnesses promote FEV(1) decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am. J. Respir. Crit. Care Med. 2001; 164: 358–364.
(check this in PDF content)
44
Vestbo J., Edwards L.D., Scanlon P.D. et al. Changes in forced expiratory volume in 1 second over time in COPD. N. Engl. J. Med. 2011; 365: 1184–1192.
(check this in PDF content)
45
Seemungal T.A., Donaldson G.C., Bhowmik A. et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2000; 161: 1608–1613. Пульмонология. 2016; 26 (5): 591–603
(check this in PDF content)
46
Celli B.R., Thomas N.E., Anderson J.A. et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am. J. Respir. Crit. Care Med.2008; 178: 332–338.
(check this in PDF content)
47
Donaldson G.C., Wilkinson T.M., Hurst J.R. et al. Exacerbations and time spent outdoors in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2005; 171: 446–452.
(check this in PDF content)
48
Effing T.W., Kerstjens H.A., Monninkhof E.M. et al. Definitions of exacerbations: does it really matter in clinical trials on COPD? Chest. 2009; 136: 918–923.
(check this in PDF content)
49
Tashkin D.P., Celli B., Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N. Engl. J. Med.2008; 359: 1543–1554.
(check this in PDF content)
50
Calverley P.M., Anderson J.A., Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N. Engl. J. Med. 2007; 356: 775–789.
(check this in PDF content)
51
Beeh K.M., Hederer B., Glaab T. et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int. J. Chron. Obstruct. Pulm. Dis. 2009; 4: 119–125.
(check this in PDF content)
52
Aaron S.D., Fergusson D., Marks G.B. et al. Counting, analysing and reporting exacerbations of COPD in randomised controlled trials. Thorax. 2008; 63: 122–128.
(check this in PDF content)
53
Leidy N.K., Wilcox T.K., Jones P.W. et al. Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am. J. Respir. Crit. Care Med.2011; 183: 323–329.
(check this in PDF content)
54
Anthonisen N.R., Skeans M.A., Wise R.A. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann. Intern. Med. 2005; 142: 233–239.
(check this in PDF content)
55
Au D.H., Bryson C.L., Chien J.W. et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations.J. Gen. Intern. Med. 2009; 24: 457–463.
(check this in PDF content)
56
Christenhusz L.C., Prenger R., Pieterse M.E. et al. Costeffectiveness of an intensive smoking cessation intervention for COPD outpatients. Nicotine Tob. Res.2012; 14: 657–663.
(check this in PDF content)
57
Godtfredsen N.S., Lam T.H., Hansel T.T. et al. COPDrelated morbidity and mortality after smoking cessation: status of the evidence.Eur. Respir. J.2008; 32: 844–853.
(check this in PDF content)
58
Wongsurakiat P., Maranetra K.N., Wasi C. et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004; 125: 2011–2020.
(check this in PDF content)
59
Walters J.A., Smith S., Poole P. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2010; 11: CD001390.
(check this in PDF content)
60
Nichol K.L., Baken L., Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease.Ann. Intern.Med. 1999; 130: 397–403.
(check this in PDF content)
61
Granger R., Walters J., Poole P.J. et al. Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2006; 4:CD001390.
(check this in PDF content)
62
Alfageme I., Vazquez R., Reyes N. et al. Clinical efficacy of antipneumococcal vaccination in patients with COPD. Thorax.2006; 61: 189–195.
(check this in PDF content)
63
Collet J.P., Shapiro P., Ernst P. et al. Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease. The PARI-IS Study Steering Committee and Research Group. Prevention of Acute Respiratory Infection by an Immunostimulant. Am. J. Respir. Crit. Care Med.1997; 156: 1719–1724.
(check this in PDF content)
64
Soler M., Mutterlein R., Cozma G. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease. Respiration. 2007; 74: 26–32.
(check this in PDF content)
65
Cazzola M. A new bacterial lysate protects by reducing infectious exacerbations in moderate to very severe COPD: a double-blind, randomized, placebo-controlled trial.Trends Med. 2006; 6: 191–199.
(check this in PDF content)
66
McCarthy B., Casey D., Devane D. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2015; 2: CD003793.
(check this in PDF content)
67
Greening N.J., Williams J.E., Hussain S.F. et al. An early rehabilitation intervention to enhance recovery during hospital admission for an exacerbation of chronic respiratory disease: randomised controlled trial. Br. Med. J.2014; 349: g4315.
(check this in PDF content)
68
Puhan M.A., Gimeno-Santos E., Scharplatz M. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2011; 10: CD005305.
(check this in PDF content)
69
Miravitlles M., D’Urzo A., Singh D., Koblizek V. Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review.Respir. Res.2016; 17: 112.
(check this in PDF content)
70
Miravitlles M., Calle M., Soler-Cataluña J.J. Clinical phenotypes of COPD: identification, definition and implications for guidelines.Arch. Bronconeumol.2012; 48: 86–98.
(check this in PDF content)
71
Goh F., Shaw J.G., Savarimuthu Francis S.M. et al. Personalizing and targeting therapy for COPD: the role of molecular and clinical biomarkers. Exp. Rev. Respir. Med. 2013; 7: 593–605.
(check this in PDF content)
72
Washko G.R., Fan V.S., Ramsey S.D. et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am. J. Respir. Crit. Care Med. 2008; 177: 164–169.
(check this in PDF content)
73
Donohue J.F., Fogarty C., Lotvall J. et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am. J. Respir. Crit. Care Med. 2010; 182: 155–162.
(check this in PDF content)
74
Dahl R., Chung K.F., Buhl R. et al. Efficacy of a new once daily long-acting inhaled b2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010; 65: 473–479.
(check this in PDF content)
75
Siler T.M., Williams J., Yegen U. et al. The effect of oncedaily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment.Am. J. Respir. Crit. Care Med.2010; 181: A4430.
(check this in PDF content)
76
Halpin D.M., Vogelmeier C., Pieper M.P. et al. Effect of tiotropium on COPD exacerbations: A systematic review. Respir. Med.2016; 114: 1–8.
(check this in PDF content)
77
Tashkin D.P. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr. Opin. Pulm. Med. 2010; 16: 97–105.
(check this in PDF content)
78
Dusser D., Bravo M.-L., Iacono P. The effect of tiotropium on exacerbations and airflow in patients with COPD. Eur. Respir. J. 2005; 27: 547–555.
(check this in PDF content)
79
Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 year’s treatment with tiotopium. Eur. Respir. J. 2002; 19: 209–216. http:// journal.pulmonology.ru
(check this in PDF content)
80
Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 1: 217–224.
(check this in PDF content)
81
D'Urzo A., Ferguson G.T., van Noord J.A. et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. http://www. ncbi.nlm.nih.gov/pubmed?term=Hirata%20K%5BAuthor% 5D&cauthor=true&cauthor_uid=22151296Respir. Res. 2011; 12: 156.
(check this in PDF content)
82
Kerwin E., Hébert J., Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur. Respir. J. 2012; 40: 1106–1114.
(check this in PDF content)
83
Buhl R., Banerji D. Profile of glycopyrronium for oncedaily treatment of moderate-to-severe COPD.Int. J. Chron. Obstruct. Pulm. Dis. 2012; 7: 729–741.
(check this in PDF content)
84
Ulrik C.S. Once-daily glycopyrronium bromide, a longacting muscarinic antagonist, for chronic obstructive pulmonary disease: a systematic review of clinical benefit. Int. J. Chron. Obstruct. Pulm. Dis.2012; 7: 673–678.
(check this in PDF content)
85
Jones P.W., Singh D., Bateman E.D. et al. Efficacy and safety of treatment with twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur. Respir. J. 2012; 40: 830–836.
(check this in PDF content)
86
Jones P. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Adv. Ther.2013; 30: 354–368.
(check this in PDF content)
87
Vogelmeier C., Hederer B., Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 364: 1093–1103.
(check this in PDF content)
88
Decramer M.L., Chapman K.R., Dahl R. et al. Oncedaily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel group study. Lancet Respir. Med.2013; 1: 524–533.
(check this in PDF content)
89
Wedzicha J.A., Donaldson G., Chuecos F. et al. Effect of aclidinium bromide on exacerbations in patients with moderate – to severe COPD: pooled analysis of phase III studies. Eur. Respir. J. 2014; 44: 1888.
(check this in PDF content)
90
Oba Y., Sarva S.T., Dias S. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016; 71: 15–25.
(check this in PDF content)
91
Wedzicha J.A., Decramer M., Ficker J.H. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, doubleblind, parallel-group study. Lancet Respir. Med.2013; 1: 199–209.
(check this in PDF content)
92
Banerji D., Fedele M.J., Chen H., Kim H.J. Dual bronchodilation with QVA149 reduces COPD exacerbations: results from the ignite program. Respirology. 2013; 18 (Suppl. 4): 1–81.
(check this in PDF content)
93
Zhong N.,93. Wang C., Zhou X. et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.Int. J. Chron. Obstruct. Pulm. Dis.2015; 10: 1015–1026.
(check this in PDF content)
94
Wedzicha J.A., Banerji D., Chapman K.R. et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N. Engl. J. Med. 2016; 374: 2222–2234.
(check this in PDF content)
95
Buhl R., Maltais F., Abrahams R. et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). Eur. Respir. J.2015; 45: 969–979.
(check this in PDF content)
96
Singh D., Jones P.W., Bateman E.D. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixeddose combinations compared with individual components and placebo in patients with COPD (ACLIFORMCOPD): a multicentre, randomised study. BMC Pulm. Med. 2014; 14: 178.
(check this in PDF content)
97
D’Urzo A.D., Rennard S.I., Kerwin E.M. et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir. Res. 2014; 15: 123.
(check this in PDF content)
98
Bateman E.D., Chapman K.R., Singh D. et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir. Res. 2015; 16: 92.
(check this in PDF content)
99
Vogelmeier C., Paggiaro P.L., Dorca J. et al. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study. Eur. Respir. J.2016; 48: 1030–1039.
(check this in PDF content)
100
Decramer M., Anzueto A., Kerwin E. et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.Lancet Respir. Med. 2014; 2: 472–486.
(check this in PDF content)
101
Suissa S., Barnes P.J. Inhaled corticosteroids in COPD: the case against.Eur. Respir. J.2009; 34: 13–16.
(check this in PDF content)
102
Postma D.S., Calverley P. Inhaled corticosteroids in COPD – a case in favour. Eur. Respir. J. 2009; 34: 10–12.
(check this in PDF content)
103
Bourbeau J., Christodoulopoulos P., Maltais F. et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax. 2007; 62: 938–943.
(check this in PDF content)
104
Barnes N.C., Qiu Y.-S., Pavord I.D. et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 736–743.
(check this in PDF content)
105
Barnes P.J., Adcock I.M., Ito K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J.2005; 25: 552–563.
(check this in PDF content)
106
Ito K., Ito M., Elliott W.M. et al. Decreased histone deacetylase activity in chronic obstructive pulmonary disease.N. Engl. J. Med. 2005; 352: 1967–1976.
(check this in PDF content)
107
Burge P.S., Calverley P.M., Jones P.W. et al. Randomised, double blind, placebo controled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Brit. Med. J. 2000; 320: 1297–1303.
(check this in PDF content)
108
Szafranski W., Cukier A., Ramirez A. et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease.Eur. Respir. J. 2003; 21: 74–81.
(check this in PDF content)
109
Calverley P.M., Boonsawat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22: 912–919.
(check this in PDF content)
110
Halpin D.M.G. Evaluating the effectiveness of combination therapy to prevent COPD exacerbations: the value of NNT analysis.Int. J. Clin. Pract.2005; 59: 1187–1194.
(check this in PDF content)
111
Wedzicha J.A., Singh D., Vestbo J. et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir. Med.2014; 108: 1153–1162.
(check this in PDF content)
112
Dransfield M.T., Bourbeau J., Jones P.W. et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol Пульмонология. 2016; 26 (5): 591–603 only for prevention of exacerbations of COPD: two replicate double-blind, parallel group, randomised controlled trials.Lancet Respir. Med. 2013; 1: 210–223.
(check this in PDF content)
113
Price D., Yawn B., Brusselle G., Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim. Care Respir. J.2013; 22: 92–100.
(check this in PDF content)
114
Ernst P., Saad N., Suissa S. Inhaled corticosteroids in COPD: the clinical evidence. Eur. Respir. J. 2015; 45: 525–537.
(check this in PDF content)
115
Suissa S., Patenaude V., Lapi F., Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013; 68: 1029–1036.
(check this in PDF content)
116
Yawn B.P., Li Y., Tian H. et al. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulm. Dis. 2013; 8: 295–304.
(check this in PDF content)
117
Kaplan A.G. Applying the wisdom of stepping down inhaled corticosteroids in patients with COPD: a proposed algorithm for clinical practice.Int. J. COPD. 2015; 10: 2535–2548.
(check this in PDF content)
118
Antoniu S.A. New therapeutic options in the management of COPD – focus on roflumilast.Int. J. Chron. Obstruct. Pulm. Dis.2011; 6: 147–155.
(check this in PDF content)
119
Calverley P.M., Sanchez-Toril F., McIvor A. et al. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.2007; 176: 154–161.
(check this in PDF content)
120
Calverley P.M., Rabe K.F., Goehring U.M. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009; 374: 685–694.
(check this in PDF content)
121
Rennard S.I., Calverley P.M.A., Goehring U.M. et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast – the importance of defining different subsets of patients with COPD.Respir. Res.2011, 12: 18.
(check this in PDF content)
122
Bateman E.D., Rabe K.F., Calverley P.M.A. et al. Roflumilast with long-acting b2-agonists for COPD: influence of exacerbation history. Eur. Respir. J.2011; 38: 553–560
(check this in PDF content)
123
Martinez F.J., Calverley P.M., Goehring U.-M. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015; 385: 857–866.
(check this in PDF content)
124
Martinez F.J., Rabe K.F., Sethi S. et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.Am. J. Respir. Crit. Care Med. 2016; 194: 559–567.
(check this in PDF content)
125
Kanoh S., Rubin B.K. Mechanisms of action and clinical application of macrolides as immunomodulatory medications.Clin. Microbiol. Rev. 2010; 23: 590–615.
(check this in PDF content)
126
Albert R.K., Connett J., Bailey W.C. et al. Azithromycin for prevention of exacerbations of COPD. N. Engl. J. Med. 2011; 365: 689–698.
(check this in PDF content)
127
Uzun S., Djamin R.S., Kluytmans J.A.J. et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebocontrolled trial. Lancet Respir. Med.2014; 2: 361–368.
(check this in PDF content)
128
Sethi A., Maloney J., Grove L. et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care. 2006; 173: 991–998.
(check this in PDF content)
129
Marin A., Garcia-Aymerich J., Sauleda J. et al; PAC-COPD Study Group. Effect of Bronchial Colonisation on Airway and Systemic Inflammation in Stable COPD. COPD. 2012; 9: 121–130.
(check this in PDF content)
130
Patel I.S., Seemungal T.A., Wilks M. et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax. 2002; 57: 759–764.
(check this in PDF content)
131
Banerjee D., Khair O.A., Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur. Respir. J.2004; 23: 685–691.
(check this in PDF content)
132
Matkovic Z., Miravitlles M. Chronic bronchial infection in COPD. Is there an infective phenotype? Respir. Med. 2013; 107: 10–22.
(check this in PDF content)
133
Sethi S., Jones P.W., Theron M.S. et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.Respir. Res.2010; 11: 10.
(check this in PDF content)
134
Vestbo J., Prescott E., Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group.Am. J. Respir. Crit. Care Med. 1996; 153: 1530–1535.
(check this in PDF content)
135
Prescott E., Lange P., Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur. Respir. J.1995; 8: 1333–1338.
(check this in PDF content)
136
Zheng J.P., Kang J., Huang S.G. et al. Effect of carbocisteine on acute exacerbation of chronic obstrucitve pulmonary disease (PEACE Study): a randomised placebocontrolled study. Lancet. 2008; 371: 2013–2018.
(check this in PDF content)
137
Yasuda H., Yamaya M., Sasaki T. et al. Carbocysteine reduces frequency of common colds and exacerbations in patients with chronic obstructive pulmonary disease. J. Am. Geriatr. Soc. 2006; 54: 378–380.
(check this in PDF content)
138
MaccióA., Madeddu C., Panzone F. et al. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Exp. Opin. Pharma$ cother.2009; 10: 693–703.
(check this in PDF content)
139
Gerrits C.M., Herings R.M.C., Leufkens H.G.M., Lammers J.W.J. N-acetylcystine reduce risk of re-hospitalization among patients with chronic obstructive pulmonary disease.Eur. Respir. J. 2003; 21: 795–798.
(check this in PDF content)
140
Tse H.N., Raiteri L., Wong K.Y. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, doubleblind, randomized, placebo-controlled HIACE study. Chest. 2013; 144: 106–118.
(check this in PDF content)
141
Zheng J.-P., Wen F.-Q., Bai C.-X. et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir. Med. 2014; 2: 187–194.
(check this in PDF content)
142
Cazzola M., Calzetta L., Page C. et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur. Respir. Rev.2015; 24: 451–461. Поступила 10.11.16 УДК 616.249036.129084 Received
(check this in PDF content)